Healx
This role involves building and refining AI-agentic workflows to help drug discovery scientists generate testable therapeutic hypotheses. The position requires translating discovery problems into agent designs, integrating agents with knowledge graphs and proprietary methods, and maintaining GenAI tools. Success includes taking agentic workflows from idea to production and operating with independence in the drug discovery pipeline.
Headquarters
Cambridge, England, United Kingdom
Company Size
51-200 employees
Founded
2014
Healx is an AI-driven drug discovery company that uses machine learning to identify existing drugs and develop new treatments for rare diseases. Their platform integrates biomedical data and computational models to predict promising drug-repurposing candidates and accelerate translation into preclinical and clinical development. Healx partners with patient groups, biopharma and research institutions to bring treatments from prediction to patient more quickly and cost‑effectively. The company’s focus is improving outcomes for people with rare conditions by shortening the path from discovery to therapy.
IU researcher, AI-powered biotech firm test tumor-shrinking drug for rare disease
May 23, 2025
Healx AI alliance with US-based Vuja De Sciences targets killer cancer recurrence
Sep 22, 2025
Healx and SCI Ventures partner to help treat paralysis using AI
Jul 15, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Healx.
Healx didn’t post a salary, so this is our estimate from similar listings.
3% above the average for this role
Healx: AI-driven drug repurposing for rare disease
Jul 22, 2021